Aug 13, 2019
Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results
Jul 29, 2019
Soligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract
Jul 08, 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
May 28, 2019
Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents
May 14, 2019
Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results
Apr 18, 2019
Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer
Apr 09, 2019
Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942
Apr 04, 2019
Soligenix Receives US Patent for Dusquetide Related Analogs
Mar 30, 2019
All in the Timing: Hour of Radiation Treatments Can Affect Mucositis for Patients With Head/Neck Cancers
Mar 26, 2019
Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results
Mar 18, 2019
Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC
Mar 11, 2019
Soligenix to Present at the Boston Oncology Investor Conference 2019
Jan 30, 2019
Safer Treatments Gain Market Traction as Cancer Occurence Continues to Grow
Jan 23, 2019
Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs
Dec 05, 2018
Soligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology
Oct 31, 2018
Global Oral Mucositis (OM) Market Insights, Epidemiology and Market Forecast to 2027: Focus on United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China
Oct 04, 2018
Soligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit
Sep 13, 2018
NIH selects Soligenix's SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator Program
Sep 06, 2018
Enzychem Lifesciences Completes Successful Investor Roadshow in Hong Kong and Singapore
Aug 08, 2018
Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results